MDS 2023 | ABNL MARRO: ongoing clinical study investigating MDS/MPN overlap syndromes
Michael Savona, MD, Vanderbilt University Medical Center, Nashville, TN, discusses the ongoing Phase I/II ABNL MARRO study (NCT04061421), which is the first international investigator-driven study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Dr Savona explains that the study is focused on chronic myelomonocytic leukemia (CMML), but further conditions have been included to establish novel therapeutics across the spectrum of MDS/MPN overlap syndromes. To conclude, Dr Savona highlights the study’s egalitarian participation model and advanced infrastructure, which are aimed to accelerate the investigation of novel therapies for patients with MDS/MPN overlap syndromes. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm: Consultancy, Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Ryvu: Consultancy, Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Other: serves on Data and Safety Monitoring Boards; TG Therapeutics: Research Funding; Incyte: Research Funding; Astex: Research Funding; Takeda: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Taiho: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Geron: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Forma: Consultancy; BMS: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: serves on Data and Safety Monitoring Boards; ALX Oncology: Research Funding.
